|
Humate-P® Package Notification
Wednesday, July 25, 2007
Read Press Release
Humate-P® Approved to Prevent Excessive Bleeding in VWD Patients
Undergoing Surgery
Monday, April 30, 2007
Read Press Release
Updated Prescribing Information
CSL Behring Announces Availability of Humate-P® with Smaller Diluent
Wednesday, February 15, 2006
Read Press Release
To stay informed about the latest news in hematology and bleeding
disorders, you or your patients may be interested in attending the conferences and meetings
listed below. CSL Behring will be participating in all of these events, so please stop
by our exhibit booth and get information on Humate-P®, speak with a CSL Behring representative,
or obtain brochures.
National Hemophilia Foundation
NHF On the Road
May 16-17, 2008
Sheraton Imperial Hotel and Convention Center
Durham, North Carolina
www.hemophilia.org
World Federation of Hemophilia
Hemophilia 2008 World Congress
June 1-5, 2008
Istanbul, Turkey
www.hemophilia2008.org
National Hemophilia Foundation
Annual Meeting
November 13-15, 2008
Denver, Colorado
www.hemophilia.org
The American Society of Hematology
50th Annual Meeting and Exposition
December 6-9, 2008
Moscone Convention Center
San Francisco, CA
www.hematology.org
Important Safety Information
Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also in indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or any of its components.
Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.
Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.
Please see accompanying full prescribing information for Humate-P®.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.
|||
||
© CSL Behring 2008. The product information presented on this site is intended for US residents only.
|
